ReviewCurrent infectious disease reports2019
Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections in Children: a Reappraisal of Vancomycin.
Review in Current infectious disease reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Bayesian Estimation of Vancomycin Exposure and Population Pharmacokinetics in Obese Patients.Antibiotics (Basel, Switzerland) · 2026Article
- Friedelin: A natural compound exhibited potent antibacterial, anti-inflammatory, and wound healing properties against MRSA-infected wounds.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Early Escalation to Vancomycin in Severe Pediatric Pneumonia With Pleural Effusion: A Case Report.Cureus · 2025Article
- Antibody-antibiotic conjugate targeted therapy for orthopedic implant-associated intracellular S. aureus infections.Journal of advanced research · 2024Article
- Presence of multiple van genes among glycopeptide non-susceptible Staphylococcus aureus exhibiting in vitro MIC creep phenomenon: A study from north-east India.The Indian journal of medical research · 2024Article
- Severe cellulitis from methicillin-resistant Staphylococcus aureus (MRSA) in a couple of preterm twins: a case report.Italian journal of pediatrics · 2024Article
- High prevalence of heteroresistance in Staphylococcus aureus is caused by a multitude of mutations in core genes.PLoS biology · 2024Article
- Heteroresistance to Colistin in Clinical Isolates ofAntibiotics (Basel, Switzerland) · 2023Article
- Metagenomic Insights for Antimicrobial Resistance Surveillance in Soils with Different Land Uses in Brazil.Antibiotics (Basel, Switzerland) · 2023Article
- Changes in the Use of Antibiotics for Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Teicoplanin combined with conventional vancomycin therapy for the treatment of pulmonary methicillin-resistantWorld journal of clinical cases · 2021Article
- Population Pharmacokinetics and Dosing Optimization of Vancomycin in Infants, Children, and Adolescents with Augmented Renal Clearance.Antimicrobial agents and chemotherapy · 2021Article
- Panton-valentine leukocidin Staphylococcus aureus severe infection in an infant: a case report and a review of the literature.Italian journal of pediatrics · 2021Review
- Acute osteoarticular infections in children are frequently forgotten multidiscipline emergencies: beyond the technical skills.EFORT open reviews · 2021Review
- Antistaphylococcal Activity and Phytochemical Analysis of Crude Extracts of Five Medicinal Plants Used in the Center of Morocco against Dermatitis.International journal of microbiology · 2019Article
- Assessment of Vancomycin MIC Creep Phenomenon in Methicillin-ResistantPakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewIn the last 50 years, vancomycin has been the agent of choice to treat infections due to methicillin-resistant Staphylococcus aureus (MRSA). However, vancomycin treatment failure is not uncommon, even when MRSA strains are fully susceptible to vancomycin. Treatment with vancomycin requires careful monitoring of drug levels as there is a potential for nephrotoxicity. Resistance to clindamycin is not infrequent, which also limits therapeutic options for treating infections due to MRSA in children. This paper reviews the current data on pharmacokinetics and pharmacodynamics and clinical efficacy of vancomycin in children. RECENT
findingsResistance to vancomycin in MRSA (MIC >2 mg/L) is infrequent; there is increasing evidence in the literature that vancomycin maybe ineffective against increasing proportion of isolates with MICs between 1 and 2 mg/L. Recent studies and meta-analyses have demonstrated that strains with high vancomycin MICs are associated with poor outcomes especially in patients with bacteremia and deep tissue infections due to MRSA. This gradual increase in vancomycin MIC has been reported as MIC creep or vancomycin heteroresistance. Patients infected with MRSA isolates that exhibit MIC creep experience poorer clinical outcomes, including delayed treatment response, increased mortality, increase rate of relapse, and extended hospitalization. There are limited data to guide vancomycin dosing in children with MRSA. Although the vancomycin area under the curve AUC
Indexed as
Identifiers
31486979What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.